Gloria Huerta-García1, José G Vazquez-Rosales1, José A Mata-Marín2, Leoncio Peregrino-Bejarano1, Eric Flores-Ruiz1, Fortino Solórzano-Santos3. 1. Pediatric Infectious Disease Department, Hospital de Pediatría, Centro Médico Nacional "Siglo XXI", IMSS, Ciudad de Mexico, México. 2. Infectious Diseases Department, Hospital de Infectología, National Medical Center "La Raza", IMSS, Ciudad de Mexico, México. 3. Unidad Médica de Alta Especialidad, Hospital de Pediatría, National Medical Center "Siglo XXI", IMSS, Ciudad de Mexico, México.
Abstract
BACKGROUND: Genotyping tests were developed to attenuate the impact of viral resistance. Information about the efficacy in genotype base antiretroviral therapy in children is rare and even more in low- and middle-income countries. METHODS: Sixteen children with antiretroviral therapy (ART) failure and triple-class drug-resistant viruses were included in this study. Protease and retrotranscriptase genotypes were available for all patients. Switch of ART regimen was guided by genotyping data. The primary end point was virological suppression (<50 copies/ml) and immunological improvement after 48 wk of treatment with the new ART regimen. RESULTS: The median age of the patients was 14.5 y (interquartile range (IQR) 11-16.5). Median HIV-1 RNA viral load was 4.2 log10 (IQR: 3.4-4.8). The primary end point was found in 11 children (69%), and 13 children (81%) had an HIV-1 RNA viral load <200 copies/ml. Median (IQR) for the baseline CD4(+) cell count was 382 cells/μl (281-686 cells/μl), whereas after 48 wk of treatment with the new ART regimen, it was 640 cells/μl (361-936 cells/μl) (P < 0.001). CONCLUSION: Darunavir/ritonavir, raltegravir, and etravirine were well tolerated in the present pediatric population. These drugs provide good options for children exposed to extensive ART. Regimens guided by genotyping data were effective for children who had ART failure and multidrug-resistant HIV-1 infection.
BACKGROUND: Genotyping tests were developed to attenuate the impact of viral resistance. Information about the efficacy in genotype base antiretroviral therapy in children is rare and even more in low- and middle-income countries. METHODS: Sixteen children with antiretroviral therapy (ART) failure and triple-class drug-resistant viruses were included in this study. Protease and retrotranscriptase genotypes were available for all patients. Switch of ART regimen was guided by genotyping data. The primary end point was virological suppression (<50 copies/ml) and immunological improvement after 48 wk of treatment with the new ART regimen. RESULTS: The median age of the patients was 14.5 y (interquartile range (IQR) 11-16.5). Median HIV-1 RNA viral load was 4.2 log10 (IQR: 3.4-4.8). The primary end point was found in 11 children (69%), and 13 children (81%) had an HIV-1 RNA viral load <200 copies/ml. Median (IQR) for the baseline CD4(+) cell count was 382 cells/μl (281-686 cells/μl), whereas after 48 wk of treatment with the new ART regimen, it was 640 cells/μl (361-936 cells/μl) (P < 0.001). CONCLUSION:Darunavir/ritonavir, raltegravir, and etravirine were well tolerated in the present pediatric population. These drugs provide good options for children exposed to extensive ART. Regimens guided by genotyping data were effective for children who had ART failure and multidrug-resistant HIV-1 infection.
Authors: J Durant; P Clevenbergh; P Halfon; P Delgiudice; S Porsin; P Simonet; N Montagne; C A Boucher; J M Schapiro; P Dellamonica Journal: Lancet Date: 1999-06-26 Impact factor: 79.321
Authors: P Rojas Sánchez; M de Mulder; E Fernandez-Cooke; L Prieto; P Rojo; S Jiménez de Ory; M José Mellado; M Navarro; J Tomas Ramos; Á Holguín Journal: Clin Microbiol Infect Date: 2015-02-11 Impact factor: 8.067
Authors: Verónica Briz; Juan A León-Leal; Claudia Palladino; David Moreno-Perez; Santiago J de Ory; Ma Isabel De José; Ma Isabel González-Tomé; César Gavilán Martín; Itziar Pocheville; José T Ramos; Manuel Leal; Ma Ángeles Muñoz-Fernández Journal: Pediatr Infect Dis J Date: 2012-03 Impact factor: 2.129
Authors: P Clevenbergh; J Durant; P Halfon; P del Giudice; V Mondain; N Montagne; J M Schapiro; C A Boucher; P Dellamonica Journal: Antivir Ther Date: 2000-03
Authors: Russell B Van Dyke; Sophia Lee; George M Johnson; Andrew Wiznia; Kathleen Mohan; Kenneth Stanley; Edward V Morse; Paul A Krogstad; Sharon Nachman Journal: Pediatrics Date: 2002-04 Impact factor: 7.124
Authors: Caroline Foster; Ali Judd; Pat Tookey; Gareth Tudor-Williams; David Dunn; Delane Shingadia; Karina Butler; Mike Sharland; Di Gibb; Hermione Lyall Journal: AIDS Patient Care STDS Date: 2009-03 Impact factor: 5.078
Authors: Annemarie M Wensing; Vincent Calvez; Huldrych F Günthard; Victoria A Johnson; Roger Paredes; Deenan Pillay; Robert W Shafer; Douglas D Richman Journal: Top Antivir Med Date: 2014 Jun-Jul